VIEW WEBSITE >>

3 known investors

Epsilogen discovers and develops antibody therapeutics across multiple immunoglobulin isotypes (IgE, IgA, IgG) for cancer treatment. The company's lead candidate, MOv18 IgE, is the first therapeutic IgE antibody in clinical development, currently in phase Ib trials for platinum-resistant ovarian cancer.

Biotech